NKTR Nektar Therapeutics

Nektar Therapeutics recently announced that data from its Phase 2b rezpegaldesleukin trials in atopic dermatitis and alopecia areata were presented in three oral sessions at the 2026 EADV Congress in Vienna, including new 6‑month off‑treatment results in severe alopecia areata and maintenance data in atopic dermatitis. The inclusion of late‑breaking multi‑omic findings from the REZOLVE‑AD biomarker sub‑study adds an unusual level of mechanistic insight that could influence how investors...

Nektar Therapeutics (NasdaqCM:NKTR) plans three oral presentations on rezpegaldesleukin at the European Academy of Dermatology & Venereology Congress 2026. The talks will share 6‑month off‑treatment durability data from the Phase 2b REZOLVE-AA trial in severe alopecia areata. Multi‑omic biomarker findings from atopic dermatitis patients on rezpegaldesleukin are also scheduled for presentation at EADV 2026. The new rezpegaldesleukin durability and biomarker readouts come in addition to a...

Nektar Therapeutics (NKTR) has drawn fresh attention after recent share price swings, with the stock down 4% over the past day and 21% over the past month on available return data. At a share price of US$57.06, Nektar Therapeutics has swung sharply lower in the short term, with the 7 day share price return down 14.63% and the 30 day share price return down 21.32%. However, the year to date share price return remains up 31.41%, hinting that recent weakness follows a stronger run earlier in the...

Key Stats for LLY StockPast week’s performance: 1. 6%52-week range: $716 to $1,293Valuation model target price: $1,834Implied upside: 54.

Key Stats for Eli Lilly StockCurrent Price: $1,183. 46Target Price (Mid): ~$2,060Street Target: ~$1,325Potential Total Return: ~74%Annualized IRR: ~14% / yearWhat Happened?Eli Lilly and Company (LLY) closed essentially flat at $1,183.

Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.3% and the

Healthcare stocks edged higher Friday afternoon, with the NYSE Healthcare Index and the State Street

All three major US stock indexes were edging higher in midday trading Friday as Treasury yields rema

(Updates to add Eli Lilly's response in the fifth and sixth paragraphs.) Nektar Therapeutics (NK

A federal jury in California has awarded Nektar Therapeutics Inc. (NASDAQ:NKTR) $90 million in damages, finding that Eli Lilly and Co. (NYSE:LLY) breached the implied covenant of good faith and fair dealing. Nektar Therapeutics Wins $90 Million Judgment Against Eli Lilly The lawsuit, filed in August 2023, stemmed from a previous licensing agreement between the two companies for the development and commercialization of the drug rezpegaldesleukin. Jury Finds Breach of Covenant The trial in the U.S

Investing.com -- Nektar Therapeutics (NASDAQ:NKTR) shares rose 3.6% in premarket trading Friday following a jury verdict awarding the company $90 million in damages in a contract dispute with Eli Lilly and Company (NYSE:LLY).

Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.

Healthcare stocks were edging higher premarket Friday, with the State Street Health Care Select Sect

On August 13, Nektar Therapeutics (NASDAQ:NKTR) held its second-quarter earnings call and laid out where its lead drug candidate stands after years of development. Rezpegaldesleukin, known as rezpeg, is now enrolling patients in Phase 3 trials for two separate autoimmune conditions, atopic dermatitis and alopecia areata. Management framed the quarter around two numbers that matter […]

Phase 3 trials for rezpegaldesleukin advance in atopic dermatitis and alopecia areata.

Nektar Therapeutics (NKTR) shares are in focus after the company reported second quarter 2026 results, with revenue of US$10.13 million and a net loss of US$40.62 million, alongside an earnings surprise relative to analyst expectations. See our latest analysis for Nektar Therapeutics. Nektar Therapeutics shares have eased in the very short term, with a 1-day share price return of 3.82% and a 7-day share price return of 4.52%. However, the stock still shows strong momentum with a year to date...

Nektar Therapeutics stock has delivered a very large gain over the past three years, yet the company now screens as expensive on broad valuation checks. After such a strong run, investors are facing a disconnect between past returns and what the current pricing suggests about future reward for risk. Nektar Therapeutics has returned almost 7x over the past three years, which raises the bar for any further upside from today's price. The launch of late stage trials for rezpegaldesleukin can...

Retail Sales Weaken in July

U.S. Stock Futures Mixed, Heads for a Winning Week.

Moby summary of Nektar Therapeutics's Q2 2026 earnings call

Nektar Therapeutics (NKTR) reports strong cash position and positive physician reception for Respeg, despite extended timelines for key data readouts.

Nektar Therapeutics (NASDAQ:NKTR) said it initiated its global Phase III ZENITH AD program for rezpegaldesleukin, or REZPEG, in moderate-to-severe atopic dermatitis during July, while also finalizing plans for a registrational Phase III trial in alopecia areata following an end-of-Phase II meeting w

Nektar (NKTR) delivered earnings and revenue surprises of +40.29% and -6.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Journey Medical (DERM) delivered earnings and revenue surprises of 0.00% and -1.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Aclaris (ACRS) delivered earnings and revenue surprises of +6.25% and +17.19%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The average of price targets set by Wall Street analysts indicates a potential upside of 104.1% in Nektar (NKTR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.